SLC29A1 antibody is human specific. SLC29A1 antibody is predicted to not cross-react with other SLC29 proteins.
Purification
SLC29A1 antibody is affinity chromatography purified via peptide column.
Immunogen
SLC29A1 antibody was raised against a 17 amino acid peptide near the center of human SLC29A1. The immunogen is located within amino acids 240 - 290 of SLC29A1.
SLC29A1
Reactivity: Human
WB, ELISA
Host: Rabbit
Polyclonal
unconjugated
Application Notes
SLC29A1 antibody can be used for detection of SLC29A1 by Western blot at 1 - 2 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 5 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
SLC29A1 antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
SLC29A1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year.
Target
SLC29A1
(Solute Carrier Family 29 (Nucleoside Transporters), Member 1 (SLC29A1))
ENT1 antibody, rENT1 antibody, 1200014D21Rik antibody, AA407560 antibody, solute carrier family 29 member 1 (Augustine blood group) antibody, solute carrier family 29 member 1 antibody, solute carrier family 29 (nucleoside transporters), member 1 antibody, SLC29A1 antibody, Slc29a1 antibody
Background
SLC29A1 is a member of the equilibrative nucleoside transporter family which plays a key role in nucleoside and nucleobase uptake for salvage pathways of nucleotide synthesis (1,2). SLC29A1 is a transmembrane glycoprotein that localizes to the plasma and mitochondrial membranes and mediates the cellular uptake of nucleosides from the surrounding medium (3). As a nucleoside transporter, SLC29A1 plays an important role in the uptake of nucleoside-based anti-cancer drugs, polymorphisms of point mutations in the gene encoding this protein may affect the efficacy of these drugs (4).